Virtual Library

Start Your Search

Matthew Meyerson



Author of

  • +

    ES 08 - Molecular Diagnostics and Targeted Therapy (ID 517)

    • Event: WCLC 2017
    • Type: Educational Session
    • Track: Chemotherapy/Targeted Therapy
    • Presentations: 1
    • +

      ES 08.05 - Oncogenomics for Clinicians (ID 7618)

      11:00 - 12:30  |  Presenting Author(s): Matthew Meyerson

      • Abstract
      • Presentation
      • Slides

      Abstract not provided

      Only Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login, select "Add to Cart" and proceed to checkout. If you would like to become a member of IASLC, please click here.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.

  • +

    MA 06 - Lung Cancer Biology I (ID 660)

    • Event: WCLC 2017
    • Type: Mini Oral
    • Track: Biology/Pathology
    • Presentations: 1
    • +

      MA 06.14 - Oncogenic SOS1 Mutations in Lung Adenocarcinoma (ID 9166)

      15:45 - 17:30  |  Author(s): Matthew Meyerson

      • Abstract
      • Presentation
      • Slides

      Background:
      Lung adenocarcinomas are characterized by genetic alterations along receptor tyrosine kinase pathways. Around 50% of lung adenocarcinomas contain alterations in KRAS and EGFR alone. Nonetheless, genetic drivers in a large proportion of other cases remain to be determined. Recent exome sequencing analysis of lung adenocarcinomas in our lab has identified SOS1, a guanine nucleotide exchange factor, as being significantly mutated in lung cancers lacking canonical oncogenic mutations. However, the functional significance of the mutations is unclear.

      Method:
      In vitro cellular assays as well as in vivo transplatation experiments were performed to determine the phenotype of SOS1 mutants. Biochemical approaches were used to determine the mechanism by which SOS1 mutants confer an oncogenic phenotype. RNA sequencing of SOS1 mutant cells was performed to transcriptionally profile the cells, and inhibitors of the RTK/Ras/MAPK pathway were tested for their efficacy against SOS1 mutants.

      Result:
      We demonstrate that ectopic expression of mutated SOS1 induces anchorage-independent cell growth in vitro and tumor formation in vivo. Biochemical experiments suggest mutant SOS1 drives over-activation of the Ras pathway, and through RNA sequencing, we identify an upregulation of MYC targets in cells expressing mutant SOS1. Furthermore, we demonstrate that cancer cells with mutant SOS1 are dependent on SOS1 for survival and are also sensitive to inhibitors of the MAPK pathway.

      Conclusion:
      Our work provides experimental evidence for the role of SOS1 as a novel oncogene and suggests possible therapeutic mechanisms to target SOS1-mutated cancers.

      Only Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login, select "Add to Cart" and proceed to checkout. If you would like to become a member of IASLC, please click here.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.

  • +

    MA 12 - Circumventing EGFR Resistance (ID 665)

    • Event: WCLC 2017
    • Type: Mini Oral
    • Track: Advanced NSCLC
    • Presentations: 1
    • +

      MA 12.06 - Using Population Dynamics Mathematical Modeling to Optimize an Intermittent Dosing Regimen for Osimertinib in EGFR-Mutant NSCLC (ID 9110)

      11:00 - 12:30  |  Author(s): Matthew Meyerson

      • Abstract
      • Presentation
      • Slides

      Background:
      Acquired resistance to therapy occurs with both first- and newer-generation epidermal growth factor receptor (EGFR) inhibitors. One strategy to delay the emergence of resistance is to use the most active/least toxic inhibitor and replace the traditional daily dosing with a biologically-rational dosing approach. Osimertinib is a covalent mutation-specific EGFR tyrosine kinase inhibitor (TKI) with activity against common EGFR plus EGFR-T790M mutations and less activity against the wild-type receptor. This drug is poised to become a 1[st] line EGFR TKI for treatment-naïve EGFR mutated lung adenocarcinomas. Therefore, it is an ideal candidate to devise rationale dosing schemes to maximize its efficacy and minimize tumor adaptation.

      Method:
      We explored pulse dosing of osimertinib, to delay the emergence of acquired resistance. We applied population dynamics mathematical modeling to this question, using key parameters (“birth rate” and “death rate”), established through cellular assays. These parameters are presumed to be dose-dependent. First, we experimentally determined the “birth-rates” of PC9 lung cancer cells, PC9 cells bearing the T790M resistance mutation, and PC9 cells that were resistant to osimertinib, with increasing concentrations of osimertinib (0 - 10μM, total of eight doses at half log intervals) using cell viability assays (MTS assay). Next, we determined cellular “death-rates” using annexin V/propidium iodide (PI) fluorescence-activated cell sorting (FACS). We then applied those parameters to our population dynamics model and simulated various treatment conditions with different dosing strategies, to identify the most effective regimens at delaying or preventing the emergence of resistance to osimertinib.

      Result:
      Using our mathematical model, we predicted that high-dose weekly treatment of osimertinib with a low maintenance dose led to minimal cell proliferation in comparison to daily dosing. Following this in silico prediction of the superiority of pulse dose treatment, we experimentally compared the frequency of emergence of resistance with different treatment dosing regimens, using a long-term cell culture system. Indeed, weekly administration of 5uM osimertinib to PC9 cells, followed by a maintenance dose of 0.25uM, suppressed the emergence of resistance for up to 5-7 weeks in culture.

      Conclusion:
      We have established a population dynamics mathematical model to predict optimal dosing regimens for osimertinib in treatment-naïve EGFR mutated lung cancers. The model was experimentally validated using a long-term culture system. Future validation in additional preclinical models (cell lines, xenografts and genetically engineered mice) can lead to rationale development of pulse-maintenance clinical trials of osimertinib and eventually establish a novel paradigm for clinical use of EGFR TKIs.

      Only Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login, select "Add to Cart" and proceed to checkout. If you would like to become a member of IASLC, please click here.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.

  • +

    P3.02 - Biology/Pathology (ID 620)

    • Event: WCLC 2017
    • Type: Poster Session with Presenters Present
    • Track: Biology/Pathology
    • Presentations: 1
    • +

      P3.02-086 - MGA Suppresses the MYC Pathway in Lung Adeocarcinoma (ID 8022)

      09:30 - 16:00  |  Author(s): Matthew Meyerson

      • Abstract
      • Slides

      Background:
      Recent exome-sequencing efforts have revealed that the MGA gene, which encodes a heterodimeric partner of the MYC-interacting protein MAX, is significantly mutated (~8%) in lung adenocarcinomas. Most MGA mutations are loss-of-function, suggesting that MGA may act as a tumor suppressor. MGA mutations are mutually exclusive to MYC gene amplification, suggesting the involvement of MGA in the MYC pathway. Here, we aimed to characterize both the cellular and molecular role of MGA in lung adenocarcinoma, with a focus on studying its role in modulating the MYC pathway.

      Method:
      Chromatin immunoprecipitation-sequencing (ChIP-seq) and RNA-sequencing (RNA-seq) analysis were used to identify MYC and MGA DNA binding sites and binding motifs. Inmunoprecipitation assays and mass spectrometry were used to elucidate MGA gene repression mechanism. Cell competition assay was performed to measure cell proliferation with and without MGA overexpression. Finally, electrophoretic mobility shift assays (EMSA) were used to functionally evaluate MGA DNA binding ability to E-boxes when missense mutations in the basic-Helix-Loop-Helix (bHLH) domain of MGA occur.

      Result:
      We found that ectopic expression of wild-type MGA represses the cellular growth of lung adenocarcinoma cell lines. Chromatin immunoprecipitation-sequencing (ChIP-seq) and RNA-sequencing (RNA-seq) analyses revealed that MGA recognizes the same DNA binding motif as MYC, shares a large proportion of genomic DNA binding sites with MYC, and represses expression of MYC target genes. Immunoprecipitation assays in combination with mass spectrometry analysis reported that MGA interacts with several gene repressing proteins and complexes, such as the Polycomb repressive complex 1 (PRC1), histone deacetylases HDAC1/2, and the E2F6 transcriptional repressor, suggesting a potential mechanism by which MGA represses its target genes. In addition, we analyzed the mutation profile of MGA on a pan-cancer scale, revealing recurrent missense mutations in the basic-Helix-Loop-Helix (bHLH) domain of MGA in other cancer types such as colorectal and endometrial carcinomas. Electrophoretic mobility shift assays (EMSA) showed that these missense mutations impair the DNA binding ability of MGA, suggesting that these missense mutations, in addition to truncation mutations, disrupt the function of MGA in cancer cells.

      Conclusion:
      In summary, our results suggest that MGA plays a tumor suppressor role by binding to and repressing MYC target genes, thus expanding our current knowledge of genomic mechanisms for MYC pathway activation in cancer.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.